Richard Pazdur

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research, DirecTV (United States)

MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 67 papers. Top paper: “FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer”.

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0991

N/A

2.9DataRank · unranked

108 citations

Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah +20 more

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3803

N/A

2.6DataRank · unranked

94 citations

Bindu Kanapuru, Bindu George, Xue Lin, Zhenzhen Xu, Wilson W. Bryan +3 more

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0459

N/A

2.2DataRank · unranked

84 citations

Diana Bradford, Michelle Marcovitz, Anup Amatya, Pallavi S. Mishra‐Kalyani, Emily Nguyen +17 more

FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1503

N/A

1.8DataRank · unranked

71 citations

Jeannette Nashed, Diana Bradford, Yi Ren, Sachia G. Khasar, Claudia P. Miller +15 more

FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2072

N/A

1.7DataRank · unranked

42 citations

Liza Stapleford, Nicole Drezner, Anup Amatya, Pallavi S. Mishra‐Kalyani, Yuan Li Shen +22 more

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2036

N/A

1.6DataRank · unranked

60 citations

Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra‐Kalyani +12 more

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2124

N/A

1.4DataRank · unranked

64 citations

Jamie R. Brewer, Jiaxin Fan, Joyce Cheng, Yuan Li Shen, Yue Xiang +6 more

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1270

N/A

1.2DataRank · unranked

46 citations

Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Lingshan Wang +14 more

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1041

N/A

1.1DataRank · unranked

38 citations

M. Naomi Horiba, Mengdie Yuan, Joyce Cheng, Steven J. Lemery, Yuan Li Shen +10 more

US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations

Journal of Clinical Oncology(2024)10.1200/jco.24.00427

N/A

0.978DataRank · unranked

41 citations

James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K. Ricks +14 more

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3652

N/A

0.773DataRank · unranked

172 citations

Tatiana M. Prowell, Jennifer Gao, Laura L. Fernandes, Emily Li, Xiling Jiang +29 more

FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2234

N/A

0.739DataRank · unranked

24 citations

Kelly J. Norsworthy, Xin Wang, Jonathon Vallejo, Edwin C.Y. Chow, Ruo‐Jing Li +7 more

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival

Journal of Clinical Oncology(2023)10.1200/jco.23.00225

N/A

0.731DataRank · unranked

130 citations

Yvette Kasamon, Marc R. Theoret, Richard Pazdur, Paul Kluetz, Nicole Gormley +1 more

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0834

N/A

0.700DataRank · unranked

105 citations

Flora Mulkey, Emma Scott, Ashley F. Ward, Donna Przepiorka, Rosane Charlab +9 more

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4462

N/A

0.626DataRank · unranked

64 citations

Shan Pradhan, Lola A. Fashoyin‐Aje, Yi Ren, Yuan-Li Shen, Yuan Xu +12 more

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1466

N/A

0.617DataRank · unranked

60 citations

Paz J. Vellanki, Erin Larkins, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Youwei Bi +11 more

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy

Journal of Clinical Oncology(2024)10.1200/jco.24.00546

N/A

0.584DataRank · unranked

15 citations

Diana Bradford, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Catherine C. Lerro, Donna R. Rivera +13 more

FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4498

N/A

0.561DataRank · unranked

41 citations

Kelly J. Norsworthy, Sriram Subramaniam, Haiyan Chen, Michael L. Manning, Eliford Kitabi +8 more

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-3247

N/A

0.553DataRank · unranked

39 citations

Christy Osgood, Anup Amatya, Mallorie H. Fiero, C.J. George Chang, Tiffany K. Ricks +32 more

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0850

N/A

0.524DataRank · unranked

32 citations

James H. Doroshow, Susan Galbraith, Antoni Ribas, Paul G. Kluetz, Richard Pazdur +2 more

FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1199

N/A

0.505DataRank · unranked

28 citations

Brian L. Heiss, Hee‐Koung Joeng, Chana Weinstock, Xin Gao, William F. Pierce +8 more

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3439

N/A

0.470DataRank · unranked

22 citations

Diana Bradford, Somak Chatterjee, Xiaoxue Li, Stephanie Aungst, Amy M. Skinner +22 more

FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0688

N/A

0.208DataRank · unranked

3 citations

Donna R. Rivera, Joseph Wynne, Jian Zhao, Robyn Konicki, Aida Kuzucan +8 more

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia

Journal of Clinical Oncology(2025)10.1200/jco-25-01369

N/A

0.104DataRank · unranked

1 citations

Dianne Pulte, Lori A. Ehrlich, Alexei Ionan, Spencer R. Haupert, Jonathon Vallejo +15 more

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3579

N/A

0DataRank · unranked

11 citations

Maryam Sarraf Yazdy, Yvette L. Kasamon, Rachel Ershler, Emily Y. Jen, Bindu Kanapuru +7 more

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

Bladder Cancer(2023)10.3233/blc-230056

N/A

0DataRank · unranked

8 citations

Noah M. Hahn, Seth P. Lerner, Jaleh Fallah, Sundeep Agrawal, Ashish M. Kamat +33 more

FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3240

N/A

0DataRank · unranked

0 citations

Julia Eckstein, Kirsten B. Goldberg, Mark C. Ascione, Thamar Bailey, Kimberly Taylor +8 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1393

N/A

0DataRank · unranked

32 citations

William F. Maguire, Chana Weinstock, Hui Zhang, Xin Gao, Fang Li +14 more

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0281

N/A

0DataRank · unranked

25 citations

Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Brian J. Christmas, Matthew D. Thompson +16 more

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0517

N/A

0DataRank · unranked

23 citations

Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup Amatya, Joyce Cheng +9 more

FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0949

N/A

0DataRank · unranked

14 citations

Diana Bradford, Yi Ren, Stephanie Aungst, Claudia P. Miller, Lili Pan +19 more

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2196

N/A

0DataRank · unranked

10 citations

Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke, Haiyan Chen, Jonathon Vallejo +12 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3738

N/A

0DataRank · unranked

18 citations

Daniel Lee, Chana Weinstock, Xin Gao, Catharine C. Bulik, Sundeep Agrawal +9 more

Improving Collection and Analysis of Overall Survival Data

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0919

N/A

0DataRank · unranked

17 citations

Nicole Gormley, Ruixiao Lu, Anup Amatya, George D. Demetri, Keith T. Flaherty +12 more

FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1729

N/A

0DataRank · unranked

7 citations

Yvette L. Kasamon, Wenjuan Gu, Lisa R. Rodriguez, Susan Jin, Vishal Bhatnagar +5 more

False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations

JCO Precision Oncology(2024)10.1200/po.24.00354

N/A

0DataRank · unranked

2 citations

Jianjin Xu, Hee‐Koung Joeng, Chana Weinstock, Brian L. Heiss, William F. Maguire +10 more

FDA Approval Summary: Capecitabine Labeling Update under Project Renewal

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1708

N/A

0DataRank · unranked

3 citations

C S Lee, William F. Pierce, Elizabeth Everhart, Adriene King-Ducre, Melanie Royce +13 more

Oncology Accelerated Approval Confirmatory Trials: When a Failed Trial Is Not a Failed Drug

Journal of Clinical Oncology(2024)10.1200/jco-24-01654

N/A

0DataRank · unranked

7 citations

Richard Pazdur, Gautam U. Mehta

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1388

N/A

0DataRank · unranked

13 citations

Mirat Shah, Lijun Zhang, Joyce Cheng, Mary Kate Bonner, Melissa A. Pegues +22 more

FDA Approval Summary: Vorasidenib for IDH -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1333

N/A

0DataRank · unranked

12 citations

Amy Barone, Stephanie Aungst, Claudia P. Miller, Suryatheja Ananthula, Youwei Bi +20 more

FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1231

N/A

0DataRank · unranked

9 citations

Elaine Chang, Hee‐Koung Joeng, Mallorie H. Fiero, Lingshan Wang, Salaheldin S. Hamed +15 more

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1005

N/A

0DataRank · unranked

5 citations

Dianne Pulte, Xin Wang, Jonathon Vallejo, Ritu Chadda, Nan Zheng +10 more

FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0896

N/A

0DataRank · unranked

4 citations

Kamar Godder, Jingyan Wang, Justin S. Collazo, Robyn Konicki, Moran Choe +15 more

FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1133

N/A

0DataRank · unranked

9 citations

Christy Osgood, Zhou Feng, Erik Bloomquist, Shenghui Tang, C.J. George Chang +8 more

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3901

N/A

0DataRank · unranked

101 citations

Adnan A. Jaigirdar, Flora Mulkey, Joyce Cheng, Salaheldin S. Hamed, Yangbing Li +16 more

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0327

N/A

0DataRank · unranked

580 citations

Lola A. Fashoyin‐Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela Gallagher +7 more

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-3074

N/A

0DataRank · unranked

309 citations

Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yajun Liu, Hong Zhao +11 more

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0557

N/A

0DataRank · unranked

180 citations

Leigh Marcus, Lola A. Fashoyin‐Aje, Sirisha L. Mushti, Joyce Cheng, Yuan Li Shen +8 more

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4557

N/A

0DataRank · unranked

164 citations

Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow +14 more

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4271

N/A

0DataRank · unranked

82 citations

Kelly J. Norsworthy, Yaping Wang, Qing Xu, Hisham Qosa, Ramadevi Gudi +8 more

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2600

N/A

0DataRank · unranked

72 citations

Preeti Narayan, Christy Osgood, Suparna Wedam, Tatiana M. Prowell, Jennifer Gao +17 more

FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4338

N/A

0DataRank · unranked

57 citations

Flora Mulkey, Adnan A. Jaigirdar, Lisa Rodríguez, Yibo Wang, Yuan Xu +14 more

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2334

N/A

0DataRank · unranked

45 citations

Chana Weinstock, Lijun Zhang, Mallorie H. Fiero, Miao Zhao, Eias Zahalka +14 more

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4912

N/A

0DataRank · unranked

29 citations

Mallorie H. Fiero, Erik Bloomquist, A. K. Sinha, Steven J. Lemery, Harpreet Singh +13 more

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2599

N/A

0DataRank · unranked

23 citations

Preeti Narayan, Gwynn Ison, Tara Berman, Daniel L. Suzman, Suparna Wedam +18 more

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4429

N/A

0DataRank · unranked

4 citations

Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri‐Kordestani +13 more

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2875

N/A

0DataRank · unranked

231 citations

Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John +14 more

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1054

N/A

0DataRank · unranked

175 citations

Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman +17 more

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4176

N/A

0DataRank · unranked

56 citations

Robert Q. Le, Alexei Ionan, Ruo‐Jing Li, Yinghong Wang, Ramadevi Gudi +16 more

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0618

N/A

0DataRank · unranked

56 citations

Rachel Ershler, Bindu Kanapuru, Qing Xu, Guoxiang Shen, Liang Li +8 more

Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition

Nature Medicine(2022)10.1038/s41591-022-01775-6

N/A

0DataRank · unranked

52 citations

Bobby Daly, Mary Gospodarowicz, Monica M. Bertagnolli, Otis W. Brawley, Bruce A. Chabner +29 more

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0873

N/A

0DataRank · unranked

48 citations

Amy Barone, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Emasenyie Isikwei +14 more

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2400

N/A

0DataRank · unranked

12 citations

Leslie Doros, Margaret Thompson, Sirisha L. Mushti, Rosane Charlab, Elizabeth I. Spehalski +8 more

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0617

N/A

0DataRank · unranked

10 citations

Sandra J. Casak, Pallavi S. Mishra‐Kalyani, Pourab Roy, Julia A. Beaver, Richard Pazdur +4 more

FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3699

N/A

0DataRank · unranked

47 citations

Erin Larkins, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Samina Jafri, Shyam Kalavar +6 more

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1042

N/A

0DataRank · unranked

21 citations

Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Sriram Subramaniam, Hong Zhao +15 more

Driving Diversity and Inclusion in Cancer Drug Development – Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1391

N/A

0DataRank · unranked

14 citations

Craig Tendler, Bea Lavery, Serban Ghiorghiu, Brittany Gerald, Chitkala Kalidas +8 more